Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition

Impact · against what's priced in

Tarsus Pharmaceuticals is expanding its pipeline into rare inherited retinal disorders via an $800 million acquisition of Alkeus Pharmaceuticals. This provides a high-upside growth catalyst by targeting an untapped U.S. market with no approved treatments.

TARS+0.50: No priced-in read yet
In context: The acquisition of Alkeus for up to $800 million adds an experimental oral therapy for a rare retinal disorder with no current U.S. treatment, providing a significant new growth vector.
Read from the article alone

Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition

m and a
biotech
TARS
acquisition
eye care
pharmaceuticals
retinal disorder

Search tags

Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition

What matters in this story

Affle to acquire Perion, to scale its CPCU business across Developed markets

Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition

What matters in this story

Affle to acquire Perion, to scale its CPCU business across Developed markets

How each ticker is affected

Track these names every morning.

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Tenax Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TENX

AstraZeneca: 3 Key Takeaways for Long-Term Investors

Defense Giant Lockheed Martin Just Got a Little Bigger

Perion Enters into Definitive Merger Agreement with Affle

Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition

What matters in this story

Next reads from the same story arc

Affle to acquire Perion, to scale its CPCU business across Developed markets

Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition

What matters in this story

Next reads from the same story arc

Affle to acquire Perion, to scale its CPCU business across Developed markets

How each ticker is affected

Track these names every morning.

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Tenax Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TENX

AstraZeneca: 3 Key Takeaways for Long-Term Investors

Defense Giant Lockheed Martin Just Got a Little Bigger

Perion Enters into Definitive Merger Agreement with Affle